Claims

1. Use of desPro^{36}Exendin-4(1-39)-Lys$_6$-NH$_2$ or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for reducing postprandial plasma glucose concentration in a diabetes type 2 patients, wherein the diabetes type 2 patient to be treated has a 2 hours postprandial plasma glucose concentration of at least 14 mmol/L; wherein the subject to be treated does not receive an antidiabetic treatment and wherein the subject to be treated has a body mass index of at least 30 kg/m^2.

2. The use according to claim 1, wherein the subject to be treated is obese.

3. The use according to any of the preceding claims, wherein the subject to be treated is an adult subject.

4. The use of any of the preceding claims, wherein in the subject to be treated, diabetes mellitus type 2 has been diagnosed at least 1 year or at least 2 years before onset of therapy.

5. The use of any of the preceding claims, wherein the subject to be treated has a HbA_{1c} value of about 7 to about 10%.

6. The use of any of the preceding claims, wherein the subject to be treated has a fasting plasma glucose concentration of at least 8 mmol/L.

7. The use of any of the preceding claims, wherein the subject to be treated has a glucose excursion of at least 2 mmol/L, at least 3 mmol/L, at least 4 mmol/L or at least 5 mmol/L, wherein the glucose excursion is the difference of the 2 hours postprandial plasma glucose concentration and plasma glucose concentration 30 minutes prior to a meal test.

8. The use of any of the preceding claims, wherein the desPro^{36}Exendin-4(1-39)-Lys$_6$-NH$_2$ or/and the pharmaceutically acceptable salt thereof is administered parenterally.

9. The use according to any of the preceding claims, wherein the medicament is prepared for administration of desPro^{36}Exendin-4(1-39)-Lys$_6$-NH$_2$ or/and the pharmaceutically acceptable salt thereof in a daily dose selected from the range of 10 µg to 20 µg.

10. The use according to any of the preceding claims, wherein the medicament is prepared for once daily administration.

Claims

1. Use of desPro^{36}Exendin-4(1-39)-Lys$_6$-NH$_2$ or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for reducing postprandial plasma glucose concentration in a diabetes type 2 patients, wherein the diabetes type 2 patient to be treated has a 2 hours postprandial plasma glucose concentration of at least 14 mmol/L; wherein the subject to be treated does not receive an antidiabetic treatment.

2. The use according to claim 1, wherein the subject to be treated is obese.

3. The use according to claim 1 or 2, wherein the subject to be treated has a body mass index of at least 30 kg/m^2.

4. The use according to any of the preceding claims, wherein the subject to be treated is an adult subject.

5. The use of any of the preceding claims, wherein in the subject to be treated, diabetes mellitus type 2 has been diagnosed at least 1 year or at least 2 years before onset of therapy.

6. The use of any of the preceding claims, wherein the subject to be treated has a HbA_{1c} value of about 7 to about 10%.

7. The use of any of the preceding claims, wherein the subject to be treated has a fasting plasma glucose concentration of at least 8 mmol/L.

8. The use of any of the preceding claims, wherein the subject to be treated has a glucose excursion of at least 2 mmol/L, at least 3 mmol/L, at least 4 mmol/L or at least 5 mmol/L, wherein the glucose excursion is the difference of the 2 hours postprandial plasma glucose concentration and plasma glucose concentration 30 minutes prior to a meal test.

9. The use of any of the preceding claims, wherein the desPro^{36}Exendin-4(1-39)-Lys$_6$-NH$_2$ or/and the pharmaceutically acceptable salt thereof is administered parenterally.

10. The use according to any of the preceding claims, wherein the medicament is prepared for administration of desPro^{36}Exendin-4(1-39)-Lys$_6$-NH$_2$ or/and the pharmaceutically acceptable salt thereof in a daily dose selected from the range of 10 µg to 20 µg.

11. The use according to any of the preceding claims, wherein the medicament is prepared for once daily administration.